About: Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 22 October 2018

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) artículu científicu espublizáu n'ochobre de 2018 (ast) наукова стаття, опублікована в жовтні 2018 (uk) im Oktober 2018 veröffentlicher wissenschaftlicher Artikel (de) scientific article published on 22 October 2018 (en)
publication date	wds:Q58599459-6A54AD1B-1822-4B82-9735-FA9B8BF978CB
publication date	2018-10-22 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q58599459-7A58E666-868B-48E1-90EE-563CD5B7CFC2
language of work or name	English
cites work	wds:Q58599459-06CEC27F-0080-457A-B154-28EB834B1698 wds:Q58599459-0AC89DFE-04ED-43A9-A9EF-3BC090DC9294 wds:Q58599459-0B39D9AD-C047-4A96-98F7-DD1EFFEB5B8B wds:Q58599459-0C6995B0-33DF-4CF3-AE38-4FCFA302C10F wds:Q58599459-1DB9D366-0835-446B-9DE1-936CB1265443 wds:Q58599459-24E48946-1559-4F1E-80E0-4A4C2A903663 wds:Q58599459-3A8870C0-DC26-4406-89CE-13C3EE28DD74 wds:Q58599459-6C439811-EE5C-4141-B357-8A701E485191 wds:Q58599459-82F4F3AD-1BE7-4C1A-A05F-08C0DD94CCC3 wds:Q58599459-A89F3A9C-7ABE-4A89-A7B7-604464B30EC0 wds:Q58599459-A92B8722-2DF2-458D-8DFF-86A42EDF5E92 wds:Q58599459-C6568C0E-7A6E-41A6-828B-19F304D43177 wds:Q58599459-E7FEDD17-4900-44F3-BBF1-0E98C14F8C50 wds:Q58599459-F39D2331-246C-4FFA-B0A1-36BBF65E9098
cites work	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study Immune Checkpoint Blockade in Cancer Therapy Systematic review of medical treatment in melanoma: current status and future prospects. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma Measuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysis Time-dependent ROC curves for censored survival data and a diagnostic marker Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
author name string	wds:Q58599459-0AC89211-0604-47F7-84EB-3426193EC5AB wds:Q58599459-0DF7E053-1E1D-4BA8-B519-75AB89910E8B wds:Q58599459-1D68930A-5B4D-4609-8882-874DAE4383C1 wds:Q58599459-21FE3F7A-DE60-44A4-938D-3968B915FEC2 wds:Q58599459-221704BB-61B4-40DD-8743-7D25BD22F351 wds:Q58599459-47082876-5E7E-4CC6-988C-AD2295B7E653 wds:Q58599459-4830F9D0-7138-4CE3-96B0-9A21E680E9B2 wds:Q58599459-5B1406C2-C62B-4E05-BD60-FECACC0B0FAB wds:Q58599459-5F0A6A0A-9D72-4250-94F4-F97D5FA6CFA8 wds:Q58599459-912D6538-040D-4457-9C11-64B6B2828D04 wds:Q58599459-E42050C6-6A7D-4DA7-831D-B721CDF20BE9 wds:Q58599459-F9152CC2-5CBB-4A32-A6D3-F9FB33A03867 wds:Q58599459-FEDAEB5C-B2E5-4E8A-83D9-D7D919CFF49E
author name string	Andrew Hill Rene Gonzalez James Larkin David Hogg Jean-Jacques Grob Christopher D Lao Dirk Schadendorf Michael Smylie John Wagstaff Joel Jiang Jasmine Rizzo Frank Stephen Hodi Charles Lance Cowey
rdfs:label	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (en) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (nl)
skos:prefLabel	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (en) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (nl)
name	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (en) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (nl)
author	wds:Q58599459-0DCC52F9-0710-4C8D-B020-537760935E39 wds:Q58599459-2A92225B-A1FE-4746-B8C4-B7DED07ECE10 wds:Q58599459-381C1487-28AB-4609-8A19-E56D04139013 wds:Q58599459-631D722B-8258-47AB-8109-67261031AE53 wds:Q58599459-CF1D61FD-BAAE-4CB7-A5FB-DF22106DCBA0 wds:Q58599459-EF354F46-7E89-4E9A-A117-86A92E3F6510
author	Piotr Rutkowski Vanna Chiarion Sileni Reinhard Dummer Jedd D. Wolchok Pier Francesco Ferrucci Ivan Marquez-Rodas
title	wds:Q58599459-BD4BD932-C2F7-4574-A96A-C313BC52664E
title	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (en)
page(s)	wds:Q58599459-8262C68B-0EDF-443C-8AB1-C63224B984B1
page(s)	1480-1492
instance of	wds:Q58599459-757D1321-55AC-4A19-BA2D-927E7C564AC0
instance of	scholarly article
main subject	wds:Q58599459-2810738C-51FB-4536-BE6A-D44BC6CB0CC5 wds:Q58599459-DB36C034-61B2-40A8-929E-E94D4F072B8D
main subject	multicenter clinical trial phase III clinical trial
PubMed ID	wds:Q58599459-5B5D96E6-AD29-43DE-8385-62C97DF7EB39
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30361170
PubMed ID	30361170
published in	wds:Q58599459-99A6B93B-6BD8-411E-B1ED-8B185C1C832D
published in	Lancet Oncology Commission
issue	wds:Q58599459-3726FD35-13A7-49EC-88D7-764D74E4028E
volume	wds:Q58599459-50B7C51A-F20E-4193-AFA3-0928A110CE64
issue	11

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 176 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software